Despite the government’s decision last year to cancel an order for at least 100 million pills, British regulators have approved a coronavirus vaccination for adults developed by French manufacturer Valneva.

Valneva’s vaccine has been approved in the United Kingdom for the first time, and the European Medicines Agency is currently reviewing it. The two-shot vaccine is meant for adults aged 18 to 50, according to Britain’s drugs regulator, with the second dosage administered roughly a month following the first.

The Valneva vaccine is made with the decades-old technology used to manufacture shots for flu and polio. It is the sixth COVID-19 vaccine the U.K. has cleared and the only one that utilizes a “killed” virus; scientists grow the coronavirus in a lab and then inactivate the virus so it cannot replicate or infect cells.

The U.K. government scrapped an agreement with Valneva in September to purchase at least 100 million doses, saying at the time that British regulators probably would not cleared the shot. Valneva said Britain canceled the deal because of supply concerns.

Health Secretary Sajid Javid said in September that he couldn’t go into details because of commercial issues but that the deal was spiked because “it was also clear to us that the vaccine in question that the company was developing would not get approval.”

Britain was an early backer of the Valneva vaccine, agreeing to invest millions of pounds in a production facility in Scotland. As part of the contract, the U.K. had agreed to buy 100 million doses with options for another 90 million.

Even without the Valneva vaccine, the government has acquired more than enough doses to fully vaccinate everyone in the country twice. To date, nearly 60% of the British population has received three doses.